4/26/2012

Patients with low-risk asymptomatic stage 2a or 2b neuroblastoma who were treated with surgery alone had high five-year event-free and overall survival rates, Canadian researchers wrote in the Journal of Clinical Oncology. They assessed outcomes of 915 patients younger than 22 years and found that only 11.1% of them experienced disease recurrence or progression following surgery.

Related Summaries